Sutro Biopharma (NASDAQ:STRO) Upgraded to Strong-Buy at Mizuho

Mizuho upgraded shares of Sutro Biopharma (NASDAQ:STRO) to a strong-buy rating in a research report released on Monday morning,Zacks reports.

A number of other equities analysts have also issued reports on STRO. Citigroup reissued a “market outperform” rating on shares of Sutro Biopharma in a report on Thursday, August 13th. HC Wainwright lifted their target price on Sutro Biopharma from $28.00 to $50.00 and gave the company a “buy” rating in a research note on Friday, May 15th. Stifel Nicolaus set a $48.00 price target on Sutro Biopharma and gave the stock a “buy” rating in a research report on Friday, August 7th. Barclays initiated coverage on Sutro Biopharma in a research note on Thursday, May 28th. They issued an “overweight” rating and a $56.00 price target for the company. Finally, Citizens Jmp lowered their price target on Sutro Biopharma from $41.00 to $34.00 and set a “market outperform” rating on the stock in a report on Thursday, August 13th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $47.30.

Sutro Biopharma Stock Down 4.8%

Sutro Biopharma stock opened at $19.10 on Monday. The firm has a 50-day moving average price of $24.04 and a two-hundred day moving average price of $26.66. The firm has a market capitalization of $316.68 million, a price-to-earnings ratio of -1.60 and a beta of 1.48. Sutro Biopharma has a 52-week low of $7.15 and a 52-week high of $43.85.

Sutro Biopharma (NASDAQ:STRO) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($2.33) EPS for the quarter, missing the consensus estimate of ($2.19) by ($0.14). The business had revenue of $9.84 million for the quarter, compared to the consensus estimate of $11.96 million. Research analysts expect that Sutro Biopharma will post -8.41 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. AQR Capital Management LLC raised its holdings in Sutro Biopharma by 1,052.8% during the first quarter. AQR Capital Management LLC now owns 1,320,917 shares of the company’s stock worth $859,000 after purchasing an additional 1,206,330 shares in the last quarter. Orbimed Advisors LLC acquired a new stake in Sutro Biopharma in the first quarter worth approximately $19,956,000. Perceptive Advisors LLC bought a new position in Sutro Biopharma during the 1st quarter valued at $17,818,000. Jane Street Group LLC bought a new position in Sutro Biopharma during the 2nd quarter valued at $492,000. Finally, ADAR1 Capital Management LLC boosted its stake in Sutro Biopharma by 681.8% during the 1st quarter. ADAR1 Capital Management LLC now owns 524,441 shares of the company’s stock valued at $13,064,000 after purchasing an additional 457,364 shares in the last quarter. Institutional investors and hedge funds own 96.99% of the company’s stock.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.